Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1713-1729

  Arnold, D ^a   Lueza, B ^b   Douillard, J Y ^c   Peeters, M ^d   Lenz, H J ^e   Venook, A ^f   Heinemann, V ^g   Van Cutsem, E ^h   Pignon, J P ^b   Tabernero, J ^i,l   Cervantes, A ^j,k   Ciardiello, Fortunato ^l  

^a CUF Hospital   (Portugal)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c ESMO   (Switzerland)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j UNIVERSITY OF VALENCIA   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Anti EGFR treatment; Colorectal cancer; Predictive value; Prognostic; Randomized trial; Tumour side

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; ONCOGENE RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TUMOR LOCALIZATION; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; DRUG EFFECTS; FEMALE; GENETICS; MALE; METASTASIS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BEVACIZUMAB; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85027706884     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx175     Document Type: Article

References (58)

1. Richman S, Adlard J. Left and right sided large bowel cancer. Br Med J 2002; 324: 931-932
2. Hansen IO, Jess P. Possible better long-term survival in left versus rightsided colon cancer-a systematic review. Dan Med J 2012; 59: A4444
3. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United Kingdom: evidence of right-to left-sided biological gradients with implications for screening. Cancer Res 2010; 70: 5419-5429
4. Aarts F, de Hingh I, de Wilt JHW et al. Differences in outcome between right-and left-sided colon cancer: a population based study. J Clin Oncol 2013; 31(suppl 4): Abstract 493
5. Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol 2012; 65: 381-388
6. Domingo E, Ramamoorthy R, Oukrif D et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 2013; 229: 441-448
7. Slattery ML, Curtin K, Wolff RK et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009; 52: 1304-1311
8. Maus MKH, Hanna DL, Stephens C et al. Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). J Clin Oncol 2013; 31(suppl 15): Abstract 3527
9. Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001
10. LaPointe LC, Dunne R, Brown GS et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics 2008; 33: 50-64
11. Hamada H, Meno C, Watanabe D, Saijoh Y. Establishment of vertebrate left-right asymmetry. Nat Rev Genet 2002; 3: 103-113
12. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
13. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356
14. Kim SE, Paik HY, Yoon H et al. Sex-and gender-specific disparities in colorectal cancer risk. World J Gastroenterol 2015; 21: 5167-5175
15. Yamauchi M, Morikawa T, Kuchiba A et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854
16. Loupakis F, Yang D, Yau L et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107: dju427
17. Laurent-Puig P, Grisoni M-L, Heinemann V et al. MiR-31-3p is a predictive biomarker of cetuximab response in the FIRE-3 trial. Ann Oncol 2016; 27(suppl 6): Abstract 457o
18. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 101: 403-408
19. Modest DP, Schulz C, von Weikersthal LF et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs 2014; 25: 212-218
20. Seligmann JF., Elliott F, Richman SD et al. Primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 20175 patients in randomised trials. Ann Oncol 2014; 25 (suppl 4): iv172
21. Zhang Y, Ma J, Zhang S et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis 2015; 30: 1173-1183
22. Petrelli F, Tomasello G, Borgonovo K et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and metaanalysis. JAMA Oncol 2016. DOI: 10.1001/jamaoncol.2016.4227
23. Dejea CM, Wick EC, Hechenbleikner EM et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014; 111: 18321-18326
24. Brule SY, Jonker DJ, Karapetis CS et al. Location of colon cancer (rightsided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51: 1405-1414
25. Moretto R, Cremolini C, Rossini D et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist 2016; 21: 988-994
26. Chen K-H, Shao Y-Y, Chen H-M et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a mationwide cohort study. BMC Cancer 2016; 16: 327
27. Venook A, Niedzwiecki D, Innocenti F et al. Impact of primary tumor location on overall suvival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34 (suppl): Abstract 3504
28. Tejpar S, Stintzing S, Ciardiello F et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2016. DOI: 10.1001/jamaoncol.2016.4227
29. Benedix F, Kube R, Meyer F et al. Comparison of 17,641 patients with right-and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53: 57-64
30. Schrag D, Weng S, Brooks G et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol 2016; 34(suppl): Abstract 3505
31. Boisen MK, Johansen JS, Dehlendorff C et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013; 24: 2554-2559
32. Wong HL, Lee B, Field K et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer 2016; 15: e9-e15
33. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
34. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705
35. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wildtype KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247
36. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075
37. Stintzing S, Modest DP, Rossius L et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17: 1426-1434
38. Venook A, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/ leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32(suppl 15): abstract LBA 3
39. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713
40. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114
41. Bokemeyer C, Kohne CH, Ciardiello F et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015; 51: 1243-1252
42. Ye LC, Liu TS, Ren L et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938
43. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
44. Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 1346-1355
45. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019
46. Van Cutsem E, Lenz HJ, Kohne CH et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700
47. Peeters M, Douillard JY, Van Cutsem E et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-765
48. Peeters M, Oliner KS, Price TJ et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 2015; 21: 5469-5479
49. Lenz HJ, Niedzwiecki D, Innocenti F et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/ leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol 2014; 25(suppl 4): Abstract 501o
50. Modest DP, Ricard I, Heinemann V et al. Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016; 27: 1746-1753
51. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
52. Fisher DJ, Copas AJ, Tierney JF, Parmar MK. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 2011; 64: 949-967
53. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237
54. Holch JW, Ricard I, Stintzing S et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
55. Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239
56. Heinemann V, Stintzing S, Modest DP et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 2015; 51: 1927-1936
57. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
58. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546